Literature DB >> 2423274

The effects of arginine, dextran and Haemaccel infusions on urinary albumin, beta 2-microglobulin and N-acetyl-beta-D-glucosaminidase.

D S O'Reilly, E S Parry, J T Whicher.   

Abstract

Male volunteers were infused with L-arginine dextran and Haemaccel. Arginine (0.5 g/kg body weight infused over 30 min) resulted in transient highly significant increases in urinary albumin (p less than 0.001), beta 2-microglobulin (p less than 0.001) and N-acetyl-beta-D-glucosaminidase [NAG] (p less than 0.001). These effects lasted less than 120 min. Dextran 40 and 70 (500 ml infused over 2 h) did not affect urinary albumin, beta 2-microglobulin or NAG excretion. Haemaccel (8 ml/kg body weight infused over 2 h) resulted in significant increases in urinary albumin (p less than 0.05) and beta 2-microglobulin (p less than 0.01) during the second hour of the infusion. It also caused a biphasic increase in urinary NAG excretion, the initial peak (p less than 0.05) coinciding with the peak of albumin and beta 2-microglobulin excretion. The second peak which was more defined (p less than 0.01) occurred 21-24 h after the beginning of the infusion. Neither arginine or Haemaccel have been reported to be nephrotoxic whereas dextran infusions are a well recognised cause of acute tubular necrosis. These data indicate that increases in urinary beta 2-microglobulin and NAG are not always reliable indicators of nephrotoxicity or renal tubular cell damage.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423274     DOI: 10.1016/0009-8981(86)90251-2

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  2 in total

1.  Renal impairment in cardiac surgery patients receiving hydroxyethyl starch.

Authors:  Christian J Wiedermann
Journal:  Intensive Care Med       Date:  2004-01-16       Impact factor: 17.440

2.  Tubular proteinuria and enzymuria following open heart surgery.

Authors:  John Blaikley; Peter Sutton; Mary Walter; Martha Lapsley; Anthony Norden; Wilf Pugsley; Robert Unwin
Journal:  Intensive Care Med       Date:  2003-07-10       Impact factor: 17.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.